A vial of neurotoxin and a box of gloves are both “inventory,” but they don’t carry the same risk if something goes wrong. If a clinic runs out of gloves, that’s an inconvenience. If a clinic can’t quickly identify which patients received product from a specific lot — because a manufacturer flags a quality issue, or because a patient reports an unexpected reaction — that’s a problem with real clinical and regulatory weight behind it.
Most general clinic inventory systems, where they exist at all, are built around a simple count: how many units do we have left. That’s not enough for injectables, where the lot number and expiry date attached to each unit matter as much as the count itself.
Why injectables need a different inventory model
Lot-level traceability isn’t optional
Neurotoxins and dermal fillers are manufactured in batches, and manufacturers occasionally issue lot-specific recalls or safety notices. When that happens, a practice needs to answer a specific question fast: which patients received product from this lot. If lot numbers were logged in a paper notebook, or not consistently logged at all, that question takes hours of chart-by-chart searching to answer, in a situation where speed matters.
This isn’t a hypothetical compliance exercise. It’s the same reasoning behind lot tracking for any injectable pharmaceutical product, and aesthetic injectables are not exempt from it just because the procedures are elective.
Expiry tracking is a clinical safety issue, not just a cost-control one
Many injectables have shorter shelf lives than general clinic consumables, and some require specific storage conditions — refrigeration, protection from light, limited time once reconstituted or opened. A unit used after expiry, or stored outside its required conditions, is a clinical risk, not just a wasted purchase.
Manual expiry tracking — a sticky note on the fridge door, a recurring calendar reminder to “check the fridge” — works until someone’s on vacation or the practice gets busy. The failure mode isn’t dramatic; it’s just a missed week that turns into an expired vial discovered when someone reaches for it.
Reconstitution and partial-vial tracking adds another layer
Many neurotoxins are reconstituted before use and have a defined usable window afterward — often a matter of days, sometimes hours, depending on storage. A vial isn’t simply “in stock” or “used”; it can be partially used, reconstituted, and approaching its own separate expiry distinct from the unopened product’s shelf life. General inventory counts that only track whole units miss this entirely.
Multiple lots in use at once is normal, not an edge case
A busy injector might be working through the tail end of one lot while a new shipment of a different lot sits in the fridge. Without lot-level tracking, the natural tendency is to grab whatever’s most accessible rather than rotating stock by expiry — which means newer stock gets used first and older stock sits until it expires unused. First-in, first-out only works if the system tells you which is actually first.
What proper tracking looks like
Every unit logged with its lot number and expiry on arrival
When a shipment arrives, each unit should be logged against its lot number and expiry date as a discrete step, not folded into a generic “received X units” entry. This is the only way to later answer “which patients got this lot” without reconstructing it from memory.
Usage recorded at the point of treatment, tied to the patient record
When a clinician documents a treatment, the specific lot used should be recorded directly against that visit, the same way you’d record a vital sign or a procedure note. This is what makes “which patients received this lot” a database query rather than an investigation. Zdrovia’s inventory module ties stock deductions to the visit record automatically, so the lot is captured as part of normal documentation rather than a separate step someone has to remember.
Expiry alerts that surface before the deadline, not after
The system should flag units approaching expiry with enough lead time to use them, return them under supplier terms if applicable, or adjust upcoming orders — not a same-day alert that arrives too late to act on.
FIFO guidance built into the workflow
When multiple lots of the same product are in stock, the system should make it obvious which to use next based on expiry, rather than relying on staff to check dates manually every time. This keeps older stock from quietly aging out while newer stock gets reached for out of habit.
A reconstitution clock, where relevant
For products with a defined post-reconstitution window, that countdown should be tracked from the moment of reconstitution, separately from the unopened product’s expiry, with an alert as the window closes.
What this means for a med spa’s day-to-day
None of this requires more discipline from staff than they already exercise — it requires the system to carry the parts that are easy to forget under time pressure: which lot, which expiry, which patient. Logging a lot number at intake and recording it against a treatment takes seconds. Reconstructing that information after the fact, during a recall or an adverse event report, takes hours and is sometimes simply impossible if it was never captured.
Zdrovia’s inventory module supports lot and expiry tracking as part of the standard product setup, included in the free tier alongside scheduling and charting. If you’re building out the rest of a med spa’s software stack, the guide to choosing practice software for a med spa covers how inventory fits alongside consent, photo documentation, and package tracking, and the med spa solution overview shows the full workflow in one place. You can also book a walkthrough to see the lot-tracking workflow directly.